- Home
- PVLA vs OLMA Comparison
PVLA vs OLMA Comparison
Compare PVLA & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PVLA | OLMA |
|---|---|---|
| Founded | 2015 | 2006 |
| Country | United States | United States |
| Employees | 14 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | PVLA | OLMA |
|---|---|---|
| Price | $129.95 | $16.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 15 | 10 |
| Target Price | ★ $171.87 | $44.89 |
| AVG Volume (30 Days) | 228.3K | ★ 1.1M |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 15.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $102,383.52 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $20.20 | $3.89 |
| 52 Week High | $151.18 | $36.26 |
Technical Indicators
Market Signals| Indicator | PVLA | OLMA |
|---|---|---|
| Relative Strength Index (RSI) | 58.51 | 49.65 |
| Support Level | $108.99 | $13.11 |
| Resistance Level | $133.06 | $27.38 |
| Average True Range (ATR) | 9.01 | 0.81 |
| MACD | 0.64 | 0.54 |
| Stochastic Oscillator | 83.37 | 86.77 |
Price Performance
Historical ComparisonAbout PVLA Palvella Therapeutics Inc.
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.